SNHG18 inhibits Semaphorin 5A (SEMA5A) through competing endogenous RNAs (ceRNAs) to promote drug resistance in gliomas, and SNHG18 expression is related to tumor degree in gliomas [15]. Here, SNHG18 is linked to central nervous system cancer.